<SEC-DOCUMENT>0001000694-23-000039.txt : 20230509
<SEC-HEADER>0001000694-23-000039.hdr.sgml : 20230509
<ACCEPTANCE-DATETIME>20230509075902
ACCESSION NUMBER:		0001000694-23-000039
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230509
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Cost Associated with Exit or Disposal Activities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230509
DATE AS OF CHANGE:		20230509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVAVAX INC
		CENTRAL INDEX KEY:			0001000694
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				222816046
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26770
		FILM NUMBER:		23900037

	BUSINESS ADDRESS:	
		STREET 1:		21 FIRSTFIELD ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
		BUSINESS PHONE:		240-268-2000

	MAIL ADDRESS:	
		STREET 1:		21 FIRSTFIELD ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nvax-20230509.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:de25d40e-38da-4a98-8077-955a1047221d,g:5810c129-1b48-4328-aa5a-1dd4fa6ea06d,d:e6e4157019eb41859c04ad401900c521--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nvax-20230509</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV80L2ZyYWc6NTdhZjQyMjQ5Njk2NDAzZTg1YWRmYmNhMWI0Mzg3ZjcvdGFibGU6OTg1NzExNmQ2MDlhNGUwYWFkYWMzN2E1MDM0YTgyNWIvdGFibGVyYW5nZTo5ODU3MTE2ZDYwOWE0ZTBhYWRhYzM3YTUwMzRhODI1Yl8zLTEtMS0xLTE0ODM5NA_2335efb7-91ee-4be5-a9cc-c8e5329a0cc6">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV80L2ZyYWc6NTdhZjQyMjQ5Njk2NDAzZTg1YWRmYmNhMWI0Mzg3ZjcvdGFibGU6OTg1NzExNmQ2MDlhNGUwYWFkYWMzN2E1MDM0YTgyNWIvdGFibGVyYW5nZTo5ODU3MTE2ZDYwOWE0ZTBhYWRhYzM3YTUwMzRhODI1Yl80LTEtMS0xLTE0ODM5NA_0fbea106-d533-41cd-9bbc-2fb1a9a77d1a">0001000694</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nvax-20230509.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-09</xbrli:startDate><xbrli:endDate>2023-05-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie6e4157019eb41859c04ad401900c521_1"></div><div style="min-height:18pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Washington, D.C. 20549 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8xMzk4_466896ef-8fe3-4dc7-80ed-981ff32262bf">8-K</ix:nonNumeric></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:700;line-height:100%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PURSUANT TO SECTION 13 OR 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OF THE SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8yNDU_6cd27995-3335-4fb6-91f9-72c1766b5f0b">May 9, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8xMzk5_9b5538d5-6d52-4d81-9388-eb0c465324f5">NOVAVAX, INC</ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exact name of registrant as specified in charter) </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.418%"><tr><td style="width:1.0%"></td><td style="width:30.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6ZDM1OThkZDhhYjJhNDUxM2EyZTYwMGY0MGMzNDM5YmQvdGFibGVyYW5nZTpkMzU5OGRkOGFiMmE0NTEzYTJlNjAwZjQwYzM0MzliZF8wLTAtMS0xLTE0ODM5NA_53645ee9-6b08-4ca6-b67b-903545690b9a">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6ZDM1OThkZDhhYjJhNDUxM2EyZTYwMGY0MGMzNDM5YmQvdGFibGVyYW5nZTpkMzU5OGRkOGFiMmE0NTEzYTJlNjAwZjQwYzM0MzliZF8wLTItMS0xLTE0ODM5NA_7f34f4cf-7bcb-452b-b2d7-1097c9e6f963">0-26770</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6ZDM1OThkZDhhYjJhNDUxM2EyZTYwMGY0MGMzNDM5YmQvdGFibGVyYW5nZTpkMzU5OGRkOGFiMmE0NTEzYTJlNjAwZjQwYzM0MzliZF8wLTQtMS0xLTE0ODM5NA_09f2fce9-2cec-4fd9-98a1-0eaeee9e028a">22-2816046</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or Other Jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8xNDAx_6855de82-4922-487f-bb3e-84caff55ffeb">21 Firstfield Road</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8xMzk0_742e7f15-74d7-4eb1-8ee3-64ece08b8c73">Gaithersburg</ix:nonNumeric>, <ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8xMzk1_11bd4b23-4ab2-4e56-841e-eecb4c82d390">Maryland</ix:nonNumeric> <ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8zNzI_7d55f9d9-43cc-4a72-885d-566412adc85a">20878</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices, including Zip Code) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8xMzk2_205991c5-ac9e-40cd-9ce0-2e46ecc681fa">(240)</ix:nonNumeric> <ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8xMzk3_4b884a47-1a10-467c-b6c3-5538cd503ef5">268-2000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Registrant&#8217;s telephone number, including area code) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Former name or former address, if changed since last report.) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.700%"><tr><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.443%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6Y2I5MDFjZTkwNzY1NDY1M2JhZGY0MWRkYjkxMWY4MWQvdGFibGVyYW5nZTpjYjkwMWNlOTA3NjU0NjUzYmFkZjQxZGRiOTExZjgxZF8wLTEtMS0xLTE0ODM5NA_e9897799-cae0-4034-91c9-094c14857ff0">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.700%"><tr><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.443%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6NDFlODcwOWE3NGQzNDIwZjg3OTYzMjZjZTIwMTNhMjAvdGFibGVyYW5nZTo0MWU4NzA5YTc0ZDM0MjBmODc5NjMyNmNlMjAxM2EyMF8wLTEtMS0xLTE0ODM5NA_57e0ebd5-f214-4799-933c-7387842a7954">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.700%"><tr><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.443%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6ZDFjY2NiMmJjZjRkNDNkMTlmOTY4MGE4YjQ5NDhkMzEvdGFibGVyYW5nZTpkMWNjY2IyYmNmNGQ0M2QxOWY5NjgwYThiNDk0OGQzMV8wLTEtMS0xLTE0ODM5NA_405744b3-54e4-4113-afb6-6a75989385a8">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.700%"><tr><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.443%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6MjFhYjNlYzRlYzg5NGVmOTkwYjg3NGE4MzJlZTgwN2IvdGFibGVyYW5nZToyMWFiM2VjNGVjODk0ZWY5OTBiODc0YTgzMmVlODA3Yl8wLTEtMS0xLTE0ODM5NA_623d3b95-f98f-4b1c-8eee-76ecaa76b6f6">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.418%"><tr><td style="width:1.0%"></td><td style="width:40.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading <br/>Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which <br/>registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6ODEzMzdiOTA4ZTVkNDUyNWE0NzE3MjcyYzIzZmZlYTkvdGFibGVyYW5nZTo4MTMzN2I5MDhlNWQ0NTI1YTQ3MTcyNzJjMjNmZmVhOV8xLTAtMS0xLTE0ODM5NA_53d81008-3090-4101-b620-3a03d6ee3516">Common Stock, Par Value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6ODEzMzdiOTA4ZTVkNDUyNWE0NzE3MjcyYzIzZmZlYTkvdGFibGVyYW5nZTo4MTMzN2I5MDhlNWQ0NTI1YTQ3MTcyNzJjMjNmZmVhOV8xLTItMS0xLTE0ODM5NA_8388de94-b990-4078-b4a9-3bea1e1e921b">NVAX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6ODEzMzdiOTA4ZTVkNDUyNWE0NzE3MjcyYzIzZmZlYTkvdGFibGVyYW5nZTo4MTMzN2I5MDhlNWQ0NTI1YTQ3MTcyNzJjMjNmZmVhOV8xLTQtMS0xLTE0ODM5NA_1ac6a8ab-414d-4be9-bace-6f9badedb7f5">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="padding-left:216pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="padding-left:216pt;text-indent:-216pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company <ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8xNDAz_980acec5-ebf2-4c80-9355-944d6097041b">&#9744;</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie6e4157019eb41859c04ad401900c521_115"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 2.02. Results of Operations and Financial Condition.</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">First Quarter Financial Results</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On May 9, 2023, Novavax, Inc. (the &#8220;Company&#8221;) issued a press release announcing the Company&#8217;s financial results for the quarter ended March 31, 2023. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><span><br/></span></div><div id="ie6e4157019eb41859c04ad401900c521_122"></div><div><span><br/></span></div><div><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 2.05. Costs Associated with Exit or Disposal Activities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As previously announced, a near-term priority for the Company includes reducing its annual combined research and development and selling, general and administrative spend.  In connection with those plans, on May 8, 2023, the Board of Directors of the Company approved an approximately 25% reduction of its global workforce, comprised of an approximately 20% reduction in the Company&#8217;s full-time employees and the remainder comprised of contractors and consultants.  The Company expects the full annual impact of the cost savings to be realized in 2024 and approximately half of the annual impact, excluding one-time charges, to be realized in 2023 due to timing of implementing the measures, and the applicable laws, regulations, and other factors in the jurisdictions in which it operates.  The Company is expected to record a charge of approximately $10 million to $15 million related one-time employee severance and benefit costs, the majority of which is expected to be incurred in the second quarter of 2023 and it is evaluating the anticipated cost related to the consolidation of facilities and infrastructure.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><span><br/></span></div><div id="ie6e4157019eb41859c04ad401900c521_130"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 7.01. Regulation FD Disclosure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On May 9, 2023, the Company issued a press release announcing results of the Company&#8217;s Phase 2 clinical trial for combination COVID-influenza, standalone influenza, and high-dose COVID vaccines. A copy of this press release is attached as Exhibit 99.2 to this Current Report on Form 8-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information in Items 2.02, 7.01 and 9.01 of this Form 8-K (including Exhibits 99.1 and 99.2) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as expressly set forth by specific reference in such a filing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Current Report on Form 8-K includes forward-looking statements including the Company&#8217;s priorities, the size and timing of the Company&#8217;s workforce reduction, the amount and timing of the charges and cash expenditures resulting from the workforce reduction, and the expected timing and impact of cost savings from the global restructuring and cost reduction plan. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Generally, forward-looking statements can be identified through the use of words or phrases such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;possible,&#8221; &#8220;can,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;ongoing,&#8221; &#8220;consider,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;seek,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;aim,&#8221; or &#8220;assume,&#8221; the negative of these terms, or other comparable terminology, although not all forward-looking statements contain these words.  Forward-looking statements involve estimates, assumptions, risks, and uncertainties that could cause actual results or outcomes to differ materially from those expressed or implied in any forward-looking statements, and, therefore, you should not place considerable reliance on any such forward-looking statements.&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Such risks and uncertainties include, among others, that the workforce reduction may be larger than currently anticipated, the Company may incur additional costs not currently contemplated, and other risks and uncertainties are identified under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s most recent Annual Report on Form 10-K and in any subsequent filings with the Securities and Exchange Commission.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Further, any forward-looking statement speaks only as of the date when it is made, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. New factors emerge from time to time, and it is not possible for the Company to predict which factors will arise. In addition, the Company cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie6e4157019eb41859c04ad401900c521_10"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 9.01. Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.276%"><tr><td style="width:1.0%"></td><td style="width:9.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1q23earningspressrelease_.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1q23earningspressrelease_.htm">Press release, dated May 9, 2023, regarding the Company&#8217;s financial results for the quarter ended March&#160;31</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1q23earningspressrelease_.htm">, 2023</a></span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1q23earningspressrelease_.htm">.</a></span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cicpressrelease_final.htm">99.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cicpressrelease_final.htm">Press release, dated May 9, 2023, regarding results of the Company&#8217;s Phase 2 clinical trial for combination COVID-influenza, standalone influenza, and high-dose COVID vaccines.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL).</span></td></tr></table></div><div id="ie6e4157019eb41859c04ad401900c521_13"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SIGNATURES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.418%"><tr><td style="width:1.0%"></td><td style="width:47.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOVAVAX, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 9, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John A. Herrmann III</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John A. Herrmann III</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Legal Officer and Corporate Secretary</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a1q23earningspressrelease_.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia2068ef2e7a448a99d5556ea64dcab5a_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:71px;margin-bottom:5pt;vertical-align:text-bottom;width:163px"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Novavax Reports First Quarter 2023 Financial Results and Operational Highlights </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt">Announced global restructuring and cost reduction initiative with expected 2024 full-year R&#38;D and SG&#38;A reduction of approximately 40% to 50% vs 2022</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt">Provided full year 2023 total revenue guidance of between $1.4 and $1.6 billion</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt">First quarter revenue reflects shift to seasonal demand pattern&#59; on-track to deliver updated COVID vaccine for Fall season</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt">Announced positive Phase 2 topline results for COVID-Influenza Combination, standalone influenza, and high dose COVID vaccine candidates</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt">Company to host conference call today at 8&#58;30 a.m. ET</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GAITHERSBURG, Md., May 9, 2023 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8211; Novavax, Inc. (Nasdaq&#58; NVAX), a global company advancing protein-based vaccines with its novel Matrix-M</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> adjuvant, today announced its financial results and operational highlights for the first quarter ended March 31, 2023. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Today we outlined significant measures intended to reduce spend, extend our cash runway, and operate more efficiently. Combined with our focus on revenue generation from Nuvaxovid</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and management of our current liabilities, these measures should strengthen our cash position and our potential for the long-term growth and stability of Novavax,&#8221; said John C. Jacobs, President and Chief Executive Officer, Novavax. &#8220;We also made significant progress on our other key priorities, including our efforts to deliver an updated COVID vaccine for the Fall season. And, today we announced positive Phase 2 data that we believe supports the further development of our combination COVID-influenza, standalone influenza, and high-dose COVID vaccines.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Reducing our workforce has been a difficult decision, but we believe it was necessary to better align our infrastructure and scale to the endemic COVID opportunity,&#8221; continued Mr. Jacobs. &#8220;Though we still have substantial challenges ahead of us in 2023, we are encouraged by the progress we have made in the last quarter and are determined to continue executing on our top priorities.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">First Quarter 2023 and Recent Highlights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">During the quarter, the company has made progress delivering on the three near-term priorities laid out during its fourth quarter 2022 earnings call.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Priority #1&#58; Deliver an Updated, Competitive COVID Vaccine for the Upcoming 2023 Fall Vaccination Season</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Novavax remains focused on our top priority of delivering an updated, competitive COVID vaccine consistent with public health recommendations for the 2023 Fall vaccination season. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Ongoing discussions with global regulators on strain selection guidance and advancement of commercial preparedness for Fall 2023 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div><div style="padding-right:18pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.8pt">Invited to join the U.S. Food and Drug Administration&#8217;s Technology Working Group to evaluate emerging variants in preparation for strain selection at the June VRBPAC meeting</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.8pt">Ongoing development of variant strains &#8220;at risk&#8221; to support regulatory and commercial readiness </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.8pt">Modified U.S. government agreement for up to 1.5 million additional doses of Novavax&#8217;s COVID vaccine for delivery in 2023, with initial delivery supplied in five-dose vials in the first quarter of 2023</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Continued expansion of Nuvaxovid label to enable broader uptake in the long-term commercial market</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Completed enrollment and on track to receive topline results mid-2023 for Part 2 of Phase 3 strain change study, which is a regulatory prerequisite for updating our 2023-2024 vaccine composition</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Expect to file U.S. Biologics License Application in second half of 2023</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Priority #2&#58; Reduce our Rate of Spend, Manage our Cash Flow and Evolve our Scale &#38; Structure</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Novavax is focused on significantly reducing our expenses while retaining the key capabilities needed to execute our operating plans.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Announced a global restructuring and cost reduction plan, which is expected to reduce our annual combined 2024 R&#38;D and SG&#38;A expenses by approximately 40% to 50% versus 2022</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.8pt">Includes consolidation of facilities and infrastructure and approximately 25% reduction in global workforce</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.8pt">2023 R&#38;D and SG&#38;A expense reduction expected to be 20% to 25% versus 2022, based on timing of implementation, local laws and regulations and other factors, as adjusted to exclude one-time charges</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Priority #3&#58; Leverage our Technology Platform, our Capabilities and our Portfolio of Assets to Drive Additional Value Beyond Nuvaxovid Alone</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Novavax continues to leverage our pipeline and technology with the intent of delivering long-term growth and protecting global health.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Announced positive Phase 2 COVID-Influenza Combination (CIC) vaccine, standalone influenza, and high-dose COVID vaccine data, which evaluated safety and immunogenicity of different formulations </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.8pt">All three vaccine candidates were well-tolerated, demonstrated a reassuring preliminary safety profile, and had reactogenicity comparable to authorized comparators</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.8pt">Preliminary topline immune responses for all three vaccine candidates were robust</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.8pt">Additional details found here</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Serum Institute of India has received authorizations in Ghana and Nigeria for R21&#47;Matrix-M adjuvanted malaria vaccine</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.8pt">Vaccine was developed by Jenner Institute, University of Oxford, and formulated with our proprietary Matrix-M adjuvant </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div style="padding-right:18pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">First Quarter 2023 Financial Results</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:13.8pt">Total revenue&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Due to an emerging seasonal demand pattern for COVID vaccines, total revenue</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for the first quarter of 2023 was $81 million compared to $704 million in the same period in 2022. First quarter 2023 product sales include a $65 million revenue reversal associated with doses delivered in 2022 that are scheduled for future replacement.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:13.8pt">Cost of sales</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for the first quarter of 2023 were $34 million, compared to $15 million in the same period in 2022. This includes $20 million related to excess, obsolete, or expired inventory and losses on firm purchase commitments. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:13.8pt">Research and development expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (R&#38;D) for the first quarter of 2023 were $247 million, compared to $383 million in the same period in 2022. The decrease was primarily due to a reduction in clinical and manufacturing spend.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:13.8pt">Selling, general and administrative expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (SG&#38;A) for the first quarter of 2023 were $113 million, compared to $96 million for the same period in 2022. The increase is related to expansion of our commercial sales operations in Europe and commercial investment in preparation for the Fall 2023 vaccination campaign, partially offset by certain cost containment measures to reduce our operating spend.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:13.8pt">Net loss </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for the first quarter 2023 was $294 million, compared to a net income of $203 million in the same period in 2022. </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:13.8pt">Cash, cash equivalents, and restricted cash </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">were $637 million as of March 31, 2023, compared to $1.3 billion as of December 31, 2022. During the first quarter of 2023 Novavax reduced its outstanding current liabilities by $541 million, including funding the maturity of the $325 million convertible debt in January 2023.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Financial Framework and Guidance</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Full Year 2023 Guidance </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Revenue</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Full Year 2023 Guidance</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Total Revenue</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Between $1.4 billion and $1.6 billion</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:16.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant Revenue</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Between $340 million and $360 million</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:16.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Product Sales</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">2</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Between $1.06 billion and $1.24 billion</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Combined R&#38;D and SG&#38;A expenses of between $1.3 billion and $1.4 billion, as adjusted to exclude one-time restructuring costs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">3</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Secured a $100 million payment in the second quarter of 2023 related to a negotiated APA to reduce a portion of committed dose deliveries. This payment is excluded from full year 2023 sales guidance</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9.67pt">Total revenue includes Product Sales, Grants and Royalties&#47;Other</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9.67pt">APAs based on 2023 committed dose delivery schedules of approximately $800 million and U.S. market sales, subject to updated variant manufacturing and regulatory approvals</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9.67pt">Novavax expects to record a restructuring charge of $10 million to $15 million related to employee severance and benefit costs, the majority of which are expected to be incurred in the second quarter </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div style="padding-right:18pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">of 2023, and is evaluating the anticipated cost related to the consolidation of facilities and infrastructure</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Full year 2023 R&#38;D expense guidance excludes the potential costs associated with a Phase 3 Flu&#47;CIC program. We plan to evaluate our positive Phase 2 Flu&#47;CIC results announced today to frame our options to advance and finance this program via strategic collaborations and&#47;or available financing alternatives.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">2023 Liability Management</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Reduced outstanding current liabilities in the first quarter of 2023 by $541 million, including funding the maturity of the $325 million convertible debt in January 2023</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">During April 2023, addressed additional liabilities totaling $140 million, including a $27 million payment to resolve the Par arbitration and a $113 million payment to the UK government per the terms of our APA</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Conference Call</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Novavax will host its quarterly conference call today at 8&#58;30 a.m. ET. The dial-in numbers for the conference call are (877) 883-0383 (Domestic) or (412) 902-6506 (International). Participants will be prompted to request to join the Novavax, Inc. call. The passcode entry number is 3370620. A replay of the conference call will be available starting at 11&#58;30 a.m. ET on May 9, 2023 until 11&#58;59 p.m. ET on May 16, 2023. To access the replay by telephone, dial (877) 344-7529 (Domestic) or (412) 317-0088 (International) and use passcode 1969560.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A webcast of the conference call can also be accessed on the Novavax website at novavax.com&#47;events. A replay of the webcast will be available on the Novavax website until August 7, 2023.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Trade Name in the U.S.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The trade name Nuvaxovid&#8482; has not yet been approved by the U.S. Food and Drug Administration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">About Novavax</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Novavax, Inc. (Nasdaq&#58; NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world&#8217;s most urgent health challenges, Novavax is currently evaluating vaccines for COVID, influenza, and COVID and influenza combined. Please visit novavax.com and LinkedIn for more information.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Use of Non-GAAP Measures</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company has used a non-GAAP financial measure in this press release, which is R&#38;D and SG&#38;A expense, as adjusted to exclude one-time restructuring costs including a restructuring charge of $10 million to $15 million related to employee severance and benefit costs. Non-GAAP financial measures refer to financial information adjusted from financial measures prepared in accordance with accounting principles generally </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div><div style="padding-right:18pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accepted in the United States (GAAP). The Company believes that the presentation of this adjusted financial measure is useful to investors as it provides additional information on comparisons between periods by excluding certain items that affect overall comparability. The Company uses this non-GAAP financial measure for business planning purposes and to consider underlying trends of its business, and believes presenting this measure also provides useful information to investors and others for understanding and evaluating trends in the Company&#8217;s expenses in the same manner as the Company&#8217;s management. Non-GAAP financial measures should be considered in addition to, and not as an alternative for, the Company&#8217;s reported results prepared in accordance with GAAP. The use of this non-GAAP financial measure may differ from similar measures reported by other companies and may not be comparable to other similarly titled measures.  The company is unable to reconcile this forward-looking non-GAAP financial measure to the most directly comparable GAAP measure without unreasonable efforts because the company is currently unable to predict with a reasonable degree of certainty the type and extent of the anticipated costs related to the consolidation of facilities and infrastructure that would be expected to impact GAAP measure for the period but would not impact the non-GAAP measure. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Forward-Looking Statements </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Statements herein relating to the future of Novavax, its near term priorities including delivering an updated, competitive COVID vaccine for the 2023 Fall vaccination season, reducing spend, extending its cash runway and operating efficiently, the amount and impact of Novavax&#8217;s global restructuring and cost reduction plan, its operating plans, objectives and prospects full year 2023 financial guidance, its future financial or business performance, conditions or strategies, its partnerships, the timing of clinical trial results, the ongoing development of NVX-CoV2373, including Part 2 of the Phase3 strain change study, the CIC investigational vaccine candidate, the scope, timing and outcome of future and pending regulatory filings and actions, including expected U.S. Biologics License Application filing in second half of 2023, future deliveries under APAs and Novavax&#8217;s ability to advance and finance a Phase 3 Flu&#47;CIC program via strategic collaborations and &#47; or financing alternatives are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities&#59; difficulty obtaining scarce raw materials and supplies&#59; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways&#59; unanticipated challenges or delays in conducting clinical trials&#59; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities&#59; manufacturing delays or challenges, including as a result of the timing of the anticipated regulatory requirements for the Fall 2023 vaccination season&#59; the loss of future funding from the U.S. government&#59; the potential for an unfavorable outcome in disputes, including the pending arbitration with Gavi&#59; challenges in implementing our global restructuring and cost reduction plan&#59; challenges in obtaining commercial adoption of NVX-CoV2373 or a COVID variant strain-containing formulation&#59; and those other risk factors identified in the &#34;Risk Factors&#34; and &#34;Management's Discussion and Analysis of Financial Condition and Results of Operations&#34; sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div><div style="padding-right:18pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">available at www.sec.gov</font><font style="color:#00b0f0;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div><div style="padding-right:18pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOVAVAX, INC.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">(in thousands, except per share information)</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.953%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.466%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2023</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#212121;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Revenue&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Product sales</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$               (7,457)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$              585,628</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Grants</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">87,379</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">99,301</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Royalties and other</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,029</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">19,042</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total revenue</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">80,951</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">703,971</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Expenses&#58;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cost of sales</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">34,086</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">15,204</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">247,101</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">383,483</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Selling, general and administrative</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">112,532</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">95,992</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total expenses</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">393,719</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">494,679</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Income (loss) from operations</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(312,768)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">209,292</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest expense</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(4,316)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(4,876)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other income (expense)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">24,362</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,654</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Income (loss) before income tax expense</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(292,722)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">206,070</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Income tax expense (benefit)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,183</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,662</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net income (loss)</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$           (293,905)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$              203,408</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share</font></div></td><td colspan="3" style="border-top:2.5pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2.5pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Basic</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$                 (3.41)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$ &#160;&#160;&#160;&#160;         2.66</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Diluted</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$                 (3.41)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$                    2.56</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Basic</font></div></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86,158</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;76,457</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Diluted</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">86,158</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">80,711</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div><div style="padding-right:18pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SELECTED CONSOLIDATED BALANCE SHEET DATA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(in thousands)</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.462%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"><div style="padding-left:2.75pt;padding-right:1.85pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.85pt;padding-right:1.85pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</font></div><div style="padding-left:1.85pt;padding-right:1.85pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.85pt;padding-right:1.85pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</font></div><div style="padding-left:1.85pt;padding-right:1.85pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"><div style="padding-left:2.75pt;padding-right:1.85pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.75pt;padding-right:1.85pt;text-align:justify"><font><br></font></div></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:1.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:1.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">624,950</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.85pt;padding-right:-2.65pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$          </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,336,883       </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:1.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash</font></div></td><td colspan="6" style="padding:2px 2.87pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">11,993</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">11,962</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:1.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></div></td><td colspan="6" style="padding:2px 2.87pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">971,028</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,703,391</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:1.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital&#160;&#160;&#160;&#160;</font></div></td><td colspan="6" style="padding:2px 2.87pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(947,830)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(756,553)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:1.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></div></td><td colspan="6" style="padding:2px 2.87pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">1,542,699</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2,258,679</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:1.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes payable*</font></div></td><td colspan="3" style="padding:0 2.87pt 0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">491,347</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:1.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity (deficit)</font></div></td><td colspan="3" style="padding:0 2.87pt 0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(634,078)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*Included in noncurrent liabilities as of March 31, 2023 and current and non-current liabilities as of December 31, 2022.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Contacts&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Investors</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Erika Schultz &#124; 240-268-2022</font></div><div style="text-align:justify"><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ir&#64;novavax.com</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Media</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ali Chartan &#124; 240-720-7804</font></div><div style="text-align:justify"><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">media&#64;novavax.com</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></div><div style="padding-right:18pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>cicpressrelease_final.htm
<DESCRIPTION>EX-99.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia40225d69c004689921aece71e74a85d_1"></div><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccines Demonstrate Robust Immune Responses </font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt">This Phase 2 trial is evaluating three vaccine candidates&#58; COVID-Influenza Combination, stand-alone influenza and high-dose COVID</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt">Preliminary topline immune responses for all three vaccine candidates were robust versus authorized comparators</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt">For the stand-alone influenza vaccine candidate, HAI responses were 31 to 56% higher for all four influenza strains compared to Fluad</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">, and were 44 to 89% higher for A strains compared to Fluzone HD</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt">For the COVID-Influenza Combination vaccine candidate, anti-S IgG and neutralization responses achieved levels seen in Phase 3 trial with Novavax&#8217;s prototype vaccine, with&#160;HAI responses generally consistent with Fluad</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> and Fluzone HD</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt">All three vaccine candidates were well-tolerated and demonstrated a reassuring preliminary safety profile, with reactogenicity comparable to authorized comparators</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:13.8pt">These Phase 2 results support continued development for all three vaccine candidates</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GAITHERSBURG, Md., May 9, 2023</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#8211; Novavax, Inc. (Nasdaq&#58; NVAX), a global company advancing protein-based vaccines with its novel Matrix-M&#8482; adjuvant, today announced that its COVID-Influenza Combination (CIC), stand-alone influenza and high-dose COVID vaccine candidates all showed a reassuring preliminary safety profile as well as comparable reactogenicity to individual Novavax influenza and COVID vaccine candidates or authorized influenza vaccine comparators. Additionally, all three vaccines demonstrated preliminary robust immune responses. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The primary endpoint evaluated the safety of different formulations of the CIC vaccine candidate and the quadrivalent influenza vaccine candidate compared to Fluad</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;*</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and Fluzone High-Dose Quadrivalent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;**</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (Fluzone HD), as well as a high-dose COVID vaccine candidate in adults aged 50 through 80. All three vaccine candidates contained Novavax&#8217;s patented Matrix-M adjuvant and showed reassuring preliminary safety profiles and reactogenicity that was comparable to Fluad and Fluzone HD. The reactogenicity profile remained consistent as the adjuvant or antigen dose was increased.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In all groups there were no adverse events (AE) of special interest, no potentially immune mediated medical conditions and no treatment-related serious AEs. Unsolicited AEs occurred in 25% or fewer of any group and were consistent with diagnoses in the older adult population. Local and systemic symptoms were mostly mild and moderate and occurred at rates comparable to Fluad and Fluzone HD. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;The reactogenicity results support our previous observations that this technology is well suited for combination vaccines because large amounts of antigen can be incorporated without impacting tolerability,&#8221; said Filip Dubovsky President, Research and Development, Novavax. &#8220;The immune responses we observed were robust, and the data we have shared today significantly increase the probability of Phase 3 success.&#8221;</font></div><div style="margin-bottom:0.08pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The CIC vaccine candidate achieved both immunoglobulin G (IgG) and neutralizing levels comparable to Novavax&#8217;s prototype COVID vaccine (NVX-CoV2373). In addition, several of the combination formulations achieved responses to both SARS-CoV-2 and to the four homologous influenza strains that were comparable to the reference comparators, supporting their prioritization for advanced development</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:17.278%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The stand-alone influenza vaccine candidate achieved statistically significant hemagglutination inhibition (HAI) antibody responses 31 to 56% higher for all four strains compared to Fluad. Titers were 44 (H1N1) to 89% (H3N2) higher for A strains and statistically non-inferior for B-strains compared to Fluzone HD. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The highest dose stand-alone COVID vaccine candidate achieved statistically significant anti-S IgG and neutralization responses approximately 30% higher than Novavax&#8217;s prototype COVID vaccine while maintaining comparable safety and reactogenicity to currently authorized dose level of Nuvaxovid. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Today&#8217;s positive data are encouraging and further validate the value of our technology platform and its potential to improve global public health,&#8221; said John C. Jacobs, President and Chief Executive Officer, Novavax. &#8220;This is an important milestone in our journey to create additional value and diversify our portfolio of vaccines.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">About the Phase 2 Trial for CIC, Stand-alone Influenza and High-Dose COVID Vaccine Candidates </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Phase 2 Trial is a dose-confirming, randomized, observer-blinded trial evaluating the safety and effectiveness (immunogenicity) of different formulations of the CIC and influenza vaccine candidates, and higher doses of Novavax&#8217;s COVID vaccine in adults aged 50 through 80. The trial is assessing a CIC vaccine candidate comprised of Novavax's recombinant protein-based COVID vaccine, quadrivalent influenza vaccine candidate and patented saponin-based Matrix-M adjuvant. Primary and secondary objectives of the study are to assess the safety, tolerability and immune responses to various formulations of the CIC, influenza and high-dose COVID vaccine candidates. The Phase 2 dose-confirmation trial is being conducted in two parts. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">About NVX-CoV2373</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">NVX-CoV2373 is a protein-based vaccine made by creating copies of the surface spike protein of SARS-CoV-2 that causes COVID. With Novavax's unique recombinant nanoparticle technology, the non-infectious spike protein serves as the antigen that primes the immune system to recognize the virus, while Novavax&#8217;s Matrix-M adjuvant enhances and broadens the immune response. The vaccine is packaged as a ready-to-use liquid formulation and is stored at 2&#176; to 8&#176;C, enabling the use of existing vaccine supply and cold chain channels.&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">About Matrix-M&#8482; Adjuvant</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">When added to vaccines, Novavax's patented saponin-based Matrix-M adjuvant enhances the immune system response, making it broader, and more durable. The Matrix-M adjuvant stimulates the entry of antigen-presenting cells at the injection site and enhances antigen presentation in local lymph nodes.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">About Novavax</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Novavax, Inc. (Nasdaq&#58; NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world&#8217;s most urgent health challenges, Novavax is currently evaluating vaccines for COVID, influenza, and COVID and influenza combined. Please visit novavax.com and LinkedIn for more information.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Forward-Looking Statements</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Statements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, the timing of clinical trial results, the ongoing development of NVX-CoV2373, the CIC, the high-dose COVID vaccine candidates, the quadrivalent influenza investigational vaccine candidate, the scope, timing and outcome of future regulatory filings and actions, including Novavax's plans to supplement existing authorizations with data from the additional manufacturing sites in Novavax's global supply chain, additional worldwide authorizations of NVX-CoV2373 for use in adults and adolescents, and as a booster, the evolving COVID pandemic, the potential impact and reach of Novavax and NVX-CoV2373 in addressing vaccine access, controlling the pandemic and protecting populations, the efficacy, safety intended utilization, and the expected administration of NVX-CoV2373 are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities&#59; difficulty obtaining scarce raw materials and supplies&#59; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways&#59; unanticipated challenges or delays in conducting clinical trials&#59; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities&#59; and those other risk factors identified in the &#34;Risk Factors&#34; and &#34;Management's Discussion and Analysis of Financial Condition and Results of Operations&#34; sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*Fluad</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> is a registered trademark of Seqirus UK Limited</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**Fluzone High-Dose Quadrivalent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;*</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> is a registered trademark of Sanofi Pasteur Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Contacts&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Investors </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Erika Schultz</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">240-268-2022</font></div><div style="text-align:justify"><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ir&#64;novavax.com</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Media</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ali Chartan</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">240-720-7804</font></div><div style="text-align:justify"><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">media&#64;novavax.com</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>nvax-20230509.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:de25d40e-38da-4a98-8077-955a1047221d,g:5810c129-1b48-4328-aa5a-1dd4fa6ea06d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nvax="http://www.novavax.com/20230509" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.novavax.com/20230509">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvax-20230509_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvax-20230509_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.novavax.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>nvax-20230509_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:de25d40e-38da-4a98-8077-955a1047221d,g:5810c129-1b48-4328-aa5a-1dd4fa6ea06d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_46767329-57bc-4a54-a291-1bee9d7da406_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8e78f4c9-b3d4-45d9-9530-f14293fb0d46_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7d116faf-5a85-408d-b24b-1cc1a9d64108_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_8a7b8780-c029-42e5-b61a-5623ea1f0ee7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_08f0ce18-5cc0-4c9d-82d9-3e23fd898dc9_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_57453846-34fa-4d38-b29e-b0021bf71cbc_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_6a4e5fa5-b635-404b-8f79-807b5b0235c5_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_de00ec1c-f93f-4224-acfd-e07c811a0fd4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_778e4ca6-ecb1-4a0b-afb9-41cf5cee58b3_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_dca3e47d-46ff-4fc3-9d76-622493ecdf14_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4dffc133-1881-4a0c-9fe3-e4e70d557af3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_e0372964-4c3f-4d21-af07-c6e970eababc_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_5735d018-633f-4b16-a152-7312d92d3ffb_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_03772988-a966-4c3f-b320-98e215617521_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c2f50880-d9f1-4bac-b7d5-397e9f249d67_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_47c0b226-82e9-4c3a-9ea5-cb11442eb473_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f0ea9e49-6793-4e78-9926-386d26f0602c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_66006398-c536-4ab2-b430-8634b393def8_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_849470c7-b25c-4ed9-95a5-2ac6e11180a1_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_6c0d7d74-5060-4e90-9bdf-1d6ccbd954f1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f0bb1eb0-4e07-437e-99bb-6836a29a9660_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_80151067-3975-49c4-9a30-15c8adf673b8_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>nvax-20230509_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:de25d40e-38da-4a98-8077-955a1047221d,g:5810c129-1b48-4328-aa5a-1dd4fa6ea06d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.novavax.com/role/CoverPage" xlink:type="simple" xlink:href="nvax-20230509.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_873f00cc-52a4-43f7-91fd-75884b7bc5d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1b99f3a9-1959-4048-9269-96e71ecd8421" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_873f00cc-52a4-43f7-91fd-75884b7bc5d3" xlink:to="loc_dei_DocumentType_1b99f3a9-1959-4048-9269-96e71ecd8421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ebf1801a-d89c-4336-bb89-3e3975ab54ca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_873f00cc-52a4-43f7-91fd-75884b7bc5d3" xlink:to="loc_dei_DocumentPeriodEndDate_ebf1801a-d89c-4336-bb89-3e3975ab54ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a23429cb-420a-4e8c-827b-25ee97197c9a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_873f00cc-52a4-43f7-91fd-75884b7bc5d3" xlink:to="loc_dei_EntityRegistrantName_a23429cb-420a-4e8c-827b-25ee97197c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ab0d2ea0-f693-4807-a744-1035f7c7709a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_873f00cc-52a4-43f7-91fd-75884b7bc5d3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ab0d2ea0-f693-4807-a744-1035f7c7709a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_15f418d1-21cb-461c-a24d-3488329431cb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_873f00cc-52a4-43f7-91fd-75884b7bc5d3" xlink:to="loc_dei_EntityFileNumber_15f418d1-21cb-461c-a24d-3488329431cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_855ec426-2cde-4c41-9575-d15ac36002ee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_873f00cc-52a4-43f7-91fd-75884b7bc5d3" xlink:to="loc_dei_EntityTaxIdentificationNumber_855ec426-2cde-4c41-9575-d15ac36002ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_75a31487-20a6-4aeb-b07d-c75e167a6e21" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_873f00cc-52a4-43f7-91fd-75884b7bc5d3" xlink:to="loc_dei_EntityAddressAddressLine1_75a31487-20a6-4aeb-b07d-c75e167a6e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_6f9ee3d4-93ce-45d7-bc8c-d64b01546254" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_873f00cc-52a4-43f7-91fd-75884b7bc5d3" xlink:to="loc_dei_EntityAddressCityOrTown_6f9ee3d4-93ce-45d7-bc8c-d64b01546254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_781e9e4f-3308-4aa7-a0d9-e826298cca5b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_873f00cc-52a4-43f7-91fd-75884b7bc5d3" xlink:to="loc_dei_EntityAddressStateOrProvince_781e9e4f-3308-4aa7-a0d9-e826298cca5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5b4196f7-0d9b-4332-8d23-e67421235962" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_873f00cc-52a4-43f7-91fd-75884b7bc5d3" xlink:to="loc_dei_EntityAddressPostalZipCode_5b4196f7-0d9b-4332-8d23-e67421235962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c117cb75-ad1b-4fd7-9e2d-52978ce577b4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_873f00cc-52a4-43f7-91fd-75884b7bc5d3" xlink:to="loc_dei_CityAreaCode_c117cb75-ad1b-4fd7-9e2d-52978ce577b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2d8d39cc-637c-4475-acb2-194747596634" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_873f00cc-52a4-43f7-91fd-75884b7bc5d3" xlink:to="loc_dei_LocalPhoneNumber_2d8d39cc-637c-4475-acb2-194747596634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_e3c011bf-3a97-4d48-ba7c-f59a1f0ecbaf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_873f00cc-52a4-43f7-91fd-75884b7bc5d3" xlink:to="loc_dei_WrittenCommunications_e3c011bf-3a97-4d48-ba7c-f59a1f0ecbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_c65a6e43-ae5d-4cd5-be1b-c376900cb88a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_873f00cc-52a4-43f7-91fd-75884b7bc5d3" xlink:to="loc_dei_SolicitingMaterial_c65a6e43-ae5d-4cd5-be1b-c376900cb88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_f5889825-f8a9-4c6c-95a3-b0aae3297ce5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_873f00cc-52a4-43f7-91fd-75884b7bc5d3" xlink:to="loc_dei_PreCommencementTenderOffer_f5889825-f8a9-4c6c-95a3-b0aae3297ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_2a392431-75cf-4a7f-aff4-a8da44383e09" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_873f00cc-52a4-43f7-91fd-75884b7bc5d3" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_2a392431-75cf-4a7f-aff4-a8da44383e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a08a5c6b-e692-4660-a07a-082cde0b3e07" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_873f00cc-52a4-43f7-91fd-75884b7bc5d3" xlink:to="loc_dei_Security12bTitle_a08a5c6b-e692-4660-a07a-082cde0b3e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1da9fe53-93c0-45e6-9c1d-977cab17d5e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_873f00cc-52a4-43f7-91fd-75884b7bc5d3" xlink:to="loc_dei_TradingSymbol_1da9fe53-93c0-45e6-9c1d-977cab17d5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_0d81afee-45f8-4d2f-aced-649b3451a9a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_873f00cc-52a4-43f7-91fd-75884b7bc5d3" xlink:to="loc_dei_SecurityExchangeName_0d81afee-45f8-4d2f-aced-649b3451a9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b2f0a689-4339-45f2-9209-c13aae78fea2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_873f00cc-52a4-43f7-91fd-75884b7bc5d3" xlink:to="loc_dei_EntityEmergingGrowthCompany_b2f0a689-4339-45f2-9209-c13aae78fea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_060087ce-e82f-481a-94e0-24e63409bb10" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_873f00cc-52a4-43f7-91fd-75884b7bc5d3" xlink:to="loc_dei_AmendmentFlag_060087ce-e82f-481a-94e0-24e63409bb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5361bf13-f69d-4377-aa1f-da1e6fb69069" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_873f00cc-52a4-43f7-91fd-75884b7bc5d3" xlink:to="loc_dei_EntityCentralIndexKey_5361bf13-f69d-4377-aa1f-da1e6fb69069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" "F 7H# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%WVM=:I'+@<PHXZ,G!-6[G\5Y&>#7UA\'_A-_P %!?\ @M1\0?"/P:\!6/\
M:6F?"WP'I/AO39KR9[30/"VFVUM%:QRROA]L]PT'F/L62>9E<HABMPD7R>V2
M,*:_J?\ ^"''[-O@S]G#_@F3\*['PS:0FZ\9>%[3Q?KU\D(22\O-2@2YS)C[
MQBA>&W!/\%NGI7UV>8]9?AXU(Q3G>T6^FFK/*P5'ZQ-Q;TZ^9^?GAW_@T&\0
M7.BPS^*OV];6UU!H0;BUT_X:M<0Q28Y"R/J,;2*#W*(3UP.E?#__  5'_P""
M.'[0?_!,#4=.U_Q=XAL?%O@77+W['H_C#3+5K?\ TGRV?[-<V[LQ@F*I(ZJK
MR*R1L0V595_J< QP*^4/^"W7PNTKXM?\$M?C-H6J1_+IOA%];AE ^:.2PE2]
M4CTSY&T^S,.A(/R^7\0YE]<@JTN:+:35DM]-+'I5\!A_8MQ5FC\,_P#@@!^V
M?XG_ &3O^"AOA/PD=6N/^$5^*%_!X6\2::C.R237#[+"<(&"^9'=.B[R"5BG
MN ,;S7]/*'(S7\8OPQ\5:KX%^)'A_P <:%<-%>Z+KEK?V<J=4EAF61&'T90:
M_LXB.R+IT]*VXLHPAC(55O)._P O^'(RNHY4G%]#Y!_X+-_\%.]'_P"":/[,
MR^*-"M;;4/B!XMFFT[P#I%US%YRJ#-?3#.6@MU="57EY)88\H)#(G\R?C;QO
M\9OVG?C)>>-?'.N:UXT\<^,=84S7$D;W-[J5Y*PCCBCC0$DGY(XX8U 4!$10
M JC[#_X.-/VC=6^.W_!3SQ9X3_M-IM%^'5C:>'-&A61O+#K$L]V^PG:)/M4\
MT;, "RP1@\*,?5O_  :E_L,^#O%5QXO_ &\O'>E6]]>:'JK>&?!,=Q&&^Q7'
MV>.:]NP&4X<Q7$$,<BD%5:Y4YWC'I8"%#(\G^MS5YR2?W[+TZLYZWM,9BO9)
MV2_IL\S_ &6O^#5#]K#XL^#X_%W[2'QJT/X6R74(DL]"@TDZY?Q#)^6Y5)X(
M8FQA@$FE.#AMK94=-\</^#23X\>$_!\^M_ ']J[0/&>K0*SKHFO>&)-%\]5!
M.V.=;FZ4R'&U0XC3)^9T&2/WB"+C&VG;1C&*^??$F;NIS\Z]+*WY7_$[O[/P
MO+:WXG\:OQ%^'7QI_98^,E[\/OB'H&L>"_&_A/5%%Q:O(8+O3[J-A)%-%(A]
M0DL4T;%64I)&Q4JQ_H._X( _\%>-4_;Z^&=]\!_CYJJ2?%3P/8+/=:CM2,>(
MM,WK&+T(H 6:-VCCF  4F2)U_P!8R1\A_P '0?[#'@[XM?LD0_ME^'-!MX?&
M'PSN;6'4KZ&U_?:AHMS<"!K=V4;G\F>=)DW$K&K7. #*37XW?\$N/VC=4_94
M_P""@7PI^,EGK"V-C:^+[6Q\033,?*&EW;_9+PN/X@L$TCC/1T1NJBOHJGL>
M(LG=2UJD;_>NGHSSX\V Q7+?W7^1_33_ ,%'_P!D?2?VY/V,/'G[-U^D(O-<
MT9G\/7%PY1+;5(&$]G(S*"RIY\<8<J,F-I%Z,0?Y+8+GQC\,_&D=];R:AH?B
M#P_J@DC;:T-UI]Y!)D'U25)%^JLOM7]H,>V5<#I7\U?_  <@_L7Q_LM_\% ]
M0^*/AC1A:^%_B[#)XAL6B7$:ZIN"ZE$,DLSF9DNF/W1]N4# 7 \WA3&<M6>&
MGM+5?+=?-?D=.:4;Q55=-#]]/V /VK-"_;6_9 \ _M+Z*UNDGB;0(Y=6M;;/
MEVNH1LT%Y N[DK'<QS(">JJ#WKV3/>OQ(_X--?VQ/L]YX^_88\4WZB-U'BSP
M>LF=Q;]W;:A"&+<\?9)$C50>+ESGG'[:R,%3)KP<RP;P..G2Z)Z>CV.[#UO;
M45,^ /\ @XX_;07]EK_@GSJ_P[\.:O!#XG^+$S>&=-AW(TJZ>Z$ZC/Y;<M']
MG/V<L.4>]B;TK\(/^"9'['6I?MX?MM^!_P!G**VD.DWVH_;O%MQ'YB_9]'M_
MWMTV] 3&[HODQL>/-FB!ZU[M_P '$?[9X_:R_P""AFM>#?#FJ>=X5^%D;^&-
M)1&;RY+V-\ZA/ANCFYS;DCY72SB8$]:^_/\ @U1_8K3X?? 'Q)^VWXMTR,:K
M\0+I](\*R21J7AT>TE*SNK?>437:,K(>UC$PX:OJZ'_"+P^ZNTY_F]ON6IYD
M_P#;,=R]%^A^L6EZ;8Z#I4&E:180VMK:P+%;VMO&J1Q(HPJ*H "J ,    5_
M/7_P<-_\%<?&'[3'QLUK]BWX'>*YK/X9>"]2:S\1R63%?^$FU>%\2&1NKVMO
M*I2.,?(\L;3$R8@,?[9?\%'_ -H"\_98_87^*7QZT;4EL]4T#P;>-H-U(FY8
M]2E3R+,D=Q]IEAR.]?R+P6][>SQVME;37%Q,X6.&%"\DKGHH'4L3P!U)K@X7
MP-.M4EB:BNH[>N[?R-LRKRC%4X]?R/:/V'_^"?'[4?\ P4*^)4GPR_9J\"+>
M?8(TDUSQ!J<QM]+T>-FVHUS/M;!8AML2*\SA)&2-A&Y7]+/#O_!H-XONM"M[
MGQ7^WEI]CJ3PJ;JST_X;R74$<F.529]0B9U!X#&-2?05^I'_  3=_8E\"_L#
M?LA^$_V>/">FVHOK.T2\\6:G;H =5UB5%-U=,V 6!8!(]V2D,44>2$%>\[1Z
M5GCN)L=4KM8=\L5MHFWYNZ95'+J,::]IJS^7;_@HI_P0Q_;(_P"">>A7'Q+\
M06EAXV\ 1S>7)XM\+)(WV%6)"&^MG&^V#$$;P9(0613*&=5/S;\?/VDOB]^T
MWJGA[Q#\:_$TFMZOX;\*VWA^#6;LLUU>6MO)*T+7+L3YLJI*(S(<,ZQJ7W.7
M=O["_%'A?P_XQ\/7WA3Q3HEIJ6F:G9R6FHZ??6ZS074$BE)(I(V!5T925*D$
M$$@U_*!_P57_ &.K7]A3]N[QW^S[X>MKA/#MK?)J'A%[C<=VF72">&,,S%I/
M)WM;EV.6>W9N]>UD6<2S&HZ==+GBKIKJM+_,X\;A%AX\T'H^A^EO_!H 3_PC
MWQ[(_P"?WPW_ .@:G7V#_P '!'[&3?M??\$[?$E[X?T;[1XH^'#'Q7X>,:CS
M)$MHV^V0 A2[![1IBL2XWS109SM%?'O_  : \>'?CW_U_>&__0=3K]H+J))X
M'AD52&4A@PR"*^;S:M/"Y]*K#>+B_P $>AA(1J8)0?4_CI_97_:!\8_LH_M(
M>"?VC/ Z[M3\'>(K?45MO-,8NXD;$ULS@':DT)DA8_W)& K^OSX7_$;PG\7O
MAUH/Q5\ ZLFH:'XDT>VU31KZ,$+<6L\2RQ2#/(W(P//K7\J7_!6/]C63]A#]
MO#QQ\"=-T?['X<:^_M?P0JJWEMH]T3);HA8EF$)\RU+,<E[9SSUK]C/^#6_]
ML:3XV?L:ZK^S+XIU!9-;^$^K"&Q#%B\VCWADFMV9F/S,DRW46%X2)+<=QGVN
M)*,<7@:>-I]+7]'M]ST^9QY?-T:TJ,OZ:/T_K\A_^#KC]L]?!/P0\)_L0>$=
M;A_M+QQ>+KGBZWCF4R1:3:2?Z+&Z8R%GO%\Q7!'.G.O(8U^N.H7UKI]G->WM
MS'###&TDTTKA510,DDG@ #J3TK^2K_@IU^V'?_MU?MN^.OV@TOY)M%O-4:S\
M(PMO"PZ1;?N;7"-S&TD:^>ZC_EI-)ZUY/#>#^M9@JCVAK\^G^?R.S,*WLZ/*
MMWH>W?\ !O/^Q3)^UU_P4+T/Q5XBTQIO"GPK6/Q1KC,K;)+N.0#3K?(&-S7(
M$VUOE>*TF4YSBOZ8M5U/3/#NDS:MJU]#:V=I"\MS<7$@CCAC4%F=F/"J "23
M@ "OA7_@W<_8HA_9._X)]Z'XU\1Z4L/BSXI-'XGUIVC7S(K21/\ B7VQ8 -M
M6W*S;&Y26ZF%:7_!Q-^T1J/[/_\ P2X\;6F@WGV?4O'=U:^$[.0IN5H[IB]W
M&PP<A[*&[C_X&*G-*TLVS?V4-KJ*_5_?=AA8+"X3F?J_\C\4_P#@LE_P5;\?
M_P#!2/X]WFF>'M<N['X2^%]2EC\#^'E9XX[S:#'_ &I<H0N^>52Q16'[B-_+
M4;FFDEY'_@GE_P $EOVN_P#@I-JMU<_!/PY9Z7X7TNZ6#6/&WB222WTZ"0C<
M88RJ.]S.$Y,<:L$W1^:T2R(Q\9_9L^"6N?M*?M!^"?V?/#EUY%YXT\46.CQW
M9MC,MJ+B=8VG9 1N2-6:1N1\J'D5_7C^S[\"/AA^S3\&?#OP)^#WAJ'2?#?A
MG38[/3+.)1G:.6D<@#?+(Y:220_-)([NQ+,2?HLUQ\,CPT,/A4KM:>2[ONV>
M?A:$L94=2IM_6A^.S?\ !H%X@&D^<O[?EI]M\O/V?_A6+>67Q]WS/[2SC/?9
MT[=J^!?VZ?\ @EQ^VQ_P2R\9:/XK^)=AC2WU1&\,_$3P7J$QM!>1$3(HF"QS
M6ETNW>H=4),;M$T@B9E_JUVKZ5QO[0/P(^%_[2_P<\0? KXQ^&(=6\-^)M->
MSU*SF4?=)#+(A(.R6-PLD<@&Y)$1UP5!KP<+Q-F%.K^_:G#JK+;RLOSN=U3+
M:$H^YHS^0+XU?&3QW^T+\5M:^-GQ/U&&\\1>(KK[7K5Y#;K$MS<%5#S;%PJE
MR"Q"@*"QVA1@#^A#_@UK'_&LF;_LI&J_^B;2OY^?VB_@GK_[-GQ^\:?L^^*+
MAKB^\%^*+[1IKIK<Q"Y^SSO&LZJW(21561>N5=3D]:_H&_X-:_\ E&3-_P!E
M)U;_ -$VE>]Q)[-Y1#DVO&WI9V.'+^;ZV[[V9]@_MQ_L9_"+]O']F_7OV<?C
M%IP:SU:'S-,U6*%6N='OT!\B]MR?NR(2<\@.C21ME)'4_P J'[7?[)_Q@_8E
M_: U[]G3XWZ-]EUK0[C]S=0Y-OJ-JW,-Y;N<;X9%^93PRG<CA71U7^PX@'J*
M^'_^"V__  2AT+_@HY^S^VM> M,M[;XK>#K.6?P7J7F+'_:"\M)I<[,0ICE/
M,;.1Y4N&#*CS!_G<AS;^SZWLZK]R3U\GW_S^\]#'87V\.:/Q+\3YU_X-O_\
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M^V/&K[3M31[4J\ZL5(*"9C';!Q]U[E#BH/\ @H7_ ,%%_BK_ ,%#-2^'-_\
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MUWP[XA_X*Y_&B_\ "UU#-:IJ^GVTC6[ K]H@TFRAN%./XEG256[A@<U^OO\
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M/N@?'/X!:AH]]%#X;@T/4-'U;43;26QCN+B9;A&(*M$1.0R\.K#*B3>=G/\
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M1P?P-34DXQ<DKVZ#BN:5C,@^)?@:X\0GPM;^+]-DU!7V?85OD,NX9RNW.=P
M)(ZC%;R2A^!_.OBC0/@1\9AX]M]$@\(ZE9W4%\I_M-K=A;PE6!\T2\*P'48.
M21QSQ7VC"QB52PZU\/P3Q/F_$E/$2QV#=#V<DHWOJM;[I:JVK6FJL?2<29-@
M,GJ4HX7$*KS1N[6TV[='T6^A8HJ/[0F< &GJP9=PK[H^:%HHHH **** "BBB
M@ HHI&8*,F@!:J:QK6EZ#IMQJ^LZA!:6EI TUU=7,RQQPQJ"6=F8@*H )).
M *M*P89 K$^(G@+0_B=X(UCX>^)XY&TW7--GL;]87VN898RC;3V.&.#V-3+F
MY7R[]"Z?LW4BINT;J[6KMULNK$\!?$;P/\3="7Q1\//&.EZ]IKRM&NH:1?QW
M$)93AEWQDC(/4=16[7F/[+/[*WP\_9(^'4GPU^&UUJ5Q:7&J3:A=W6K722SS
M3R*B$DHB* $CC4!5'"9.22Q].J:+K2HQ=5)2MJD[I/U-\='!T\94CA9.5--\
MKDK-KHVDVD_*X4445H<H4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !32F3FG44 ,$"!MU87Q2\7+X!\
M!:GXQ\@2-8VS/'&P.&?HH..Q8C/M705G^*= T[Q3H-SX>UB'S+6\A:*XC]58
M$'!['WKEQT,14P=2.'ERU'%\K>RE;1_)V-L/*C'$0=57BFKI=5?5?-'QS#^T
MY\;8-=_M_P#X3)V_>;FLVA3R"N?N;,=,<9^][YYKZ^\ ^)#XO\%Z7XI-OY/]
MH6,5PT6[.PLH)&>^#GFO"XOV$[?^VR\GQ!D;31+GREL<3F//W=V[;NQ_%MQG
M^'M7OF@Z/8^'M#M="TN 0VUG;K#!&K$[450H&3UX%?EOAKE/'&5XC$RSR<G"
M5N52FIMROJTTW96]+]M#[3C+,.&<93H++(I27Q-1Y5:VB>BN_OMW+3W*H^#4
MD<HD&5K\Z_VMOCW\2/%WQ4US3'\47UII^EZI/9V6GVMRT<:+%(R!RJD9=L9)
M.3S@$  #V3_@FI\>?'GC^+7_ (=^-];NM4CTF.&YTZ^O)#),BNSJ\32'EE!"
ME=Q)&6&=H4#U<G\2<KSCB*654Z4EK)1D[6;C>^FZO9VW\['5F7AOFV6<,K.)
MU(M)1<H=4I6M9[.UU=:>3=CZRHKSO]I[]H'P[^S1\(-0^*GB&VDO/L[)#8:?
M%($:[N7XCCW'.T9R6;!(56(5B I^-/A3_P %F/&=]\1(=/\ C!\/='M?#=W>
M"(76C&99[",GB1_,=Q.%_B"A"1DCG"GZC,N)LERC&0PN*J<LY;*S=D]$V^BN
M>7D/ ?%'$N6U<=E^'<Z=.Z;NDVTKM13=Y-*S:7>V^A^A^:8TNUMOK3(IB\68
MS^-?GG_P5"_:_P#V@? 'QUB^$_P^\6:AX9TFQTN&Z\[3V\N;49)-Q\SS1\WE
MK@QA!@%E<G=QMWSS.L+D.7O%UTY*Z5HVO=^K2.7A'A7,.,\Z66X.48R<7)N3
M:22]$VV[I))?<C]$E.1FO/?VJ_BGXE^"?P!\2_%/PAX;75M1T73_ #[>SD5V
MC!WJIED"?,8XU8R. 1\J-\R_>'G_ /P3C^//Q'_:"_9VA\5_$\M-J5CK$UA_
M:)A$?V^-%C99L*H7/SE"5&"8R>N:^@'C25=LBY'I71A\5'-LKC7P\G%5(WBV
MM5=:.W='%C<!4X=SZ>$QL%4="I:<4_=ERRU5UK:25KVOKL?+_P#P3:_:^^+G
M[4V@>*'^*6@V,;:#=VR6FJ:?:O#'<&42%XF#,1O38I)4CY94R!PS?4*'*YJK
MI>@Z)H=FNG:+I-O9VZDE8;6$1H"3D\+@=:M@!1@497A<5@L#"CB*KJS2UDU9
MO7^D3GV/P.9YO5Q6"PZH4I-.--.ZCHD[/3=IO9)7LM HHHKT#R HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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?1A*<ZDG.;;;=VWJVWNV^K"BBBJ$%%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140473709318416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>May 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  09,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NOVAVAX, INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-26770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-2816046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">21 Firstfield Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Gaithersburg<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(240)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">268-2000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NVAX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001000694<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>nvax-20230509_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nvax-20230509.xsd" xlink:type="simple"/>
    <context id="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2023-05-09</startDate>
            <endDate>2023-05-09</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV80L2ZyYWc6NTdhZjQyMjQ5Njk2NDAzZTg1YWRmYmNhMWI0Mzg3ZjcvdGFibGU6OTg1NzExNmQ2MDlhNGUwYWFkYWMzN2E1MDM0YTgyNWIvdGFibGVyYW5nZTo5ODU3MTE2ZDYwOWE0ZTBhYWRhYzM3YTUwMzRhODI1Yl8zLTEtMS0xLTE0ODM5NA_2335efb7-91ee-4be5-a9cc-c8e5329a0cc6">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV80L2ZyYWc6NTdhZjQyMjQ5Njk2NDAzZTg1YWRmYmNhMWI0Mzg3ZjcvdGFibGU6OTg1NzExNmQ2MDlhNGUwYWFkYWMzN2E1MDM0YTgyNWIvdGFibGVyYW5nZTo5ODU3MTE2ZDYwOWE0ZTBhYWRhYzM3YTUwMzRhODI1Yl80LTEtMS0xLTE0ODM5NA_0fbea106-d533-41cd-9bbc-2fb1a9a77d1a">0001000694</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8xMzk4_466896ef-8fe3-4dc7-80ed-981ff32262bf">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8yNDU_6cd27995-3335-4fb6-91f9-72c1766b5f0b">2023-05-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8xMzk5_9b5538d5-6d52-4d81-9388-eb0c465324f5">NOVAVAX, INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6ZDM1OThkZDhhYjJhNDUxM2EyZTYwMGY0MGMzNDM5YmQvdGFibGVyYW5nZTpkMzU5OGRkOGFiMmE0NTEzYTJlNjAwZjQwYzM0MzliZF8wLTAtMS0xLTE0ODM5NA_53645ee9-6b08-4ca6-b67b-903545690b9a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6ZDM1OThkZDhhYjJhNDUxM2EyZTYwMGY0MGMzNDM5YmQvdGFibGVyYW5nZTpkMzU5OGRkOGFiMmE0NTEzYTJlNjAwZjQwYzM0MzliZF8wLTItMS0xLTE0ODM5NA_7f34f4cf-7bcb-452b-b2d7-1097c9e6f963">0-26770</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6ZDM1OThkZDhhYjJhNDUxM2EyZTYwMGY0MGMzNDM5YmQvdGFibGVyYW5nZTpkMzU5OGRkOGFiMmE0NTEzYTJlNjAwZjQwYzM0MzliZF8wLTQtMS0xLTE0ODM5NA_09f2fce9-2cec-4fd9-98a1-0eaeee9e028a">22-2816046</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8xNDAx_6855de82-4922-487f-bb3e-84caff55ffeb">21 Firstfield Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8xMzk0_742e7f15-74d7-4eb1-8ee3-64ece08b8c73">Gaithersburg</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8xMzk1_11bd4b23-4ab2-4e56-841e-eecb4c82d390">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8zNzI_7d55f9d9-43cc-4a72-885d-566412adc85a">20878</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8xMzk2_205991c5-ac9e-40cd-9ce0-2e46ecc681fa">(240)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8xMzk3_4b884a47-1a10-467c-b6c3-5538cd503ef5">268-2000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6Y2I5MDFjZTkwNzY1NDY1M2JhZGY0MWRkYjkxMWY4MWQvdGFibGVyYW5nZTpjYjkwMWNlOTA3NjU0NjUzYmFkZjQxZGRiOTExZjgxZF8wLTEtMS0xLTE0ODM5NA_e9897799-cae0-4034-91c9-094c14857ff0">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6NDFlODcwOWE3NGQzNDIwZjg3OTYzMjZjZTIwMTNhMjAvdGFibGVyYW5nZTo0MWU4NzA5YTc0ZDM0MjBmODc5NjMyNmNlMjAxM2EyMF8wLTEtMS0xLTE0ODM5NA_57e0ebd5-f214-4799-933c-7387842a7954">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6ZDFjY2NiMmJjZjRkNDNkMTlmOTY4MGE4YjQ5NDhkMzEvdGFibGVyYW5nZTpkMWNjY2IyYmNmNGQ0M2QxOWY5NjgwYThiNDk0OGQzMV8wLTEtMS0xLTE0ODM5NA_405744b3-54e4-4113-afb6-6a75989385a8">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6MjFhYjNlYzRlYzg5NGVmOTkwYjg3NGE4MzJlZTgwN2IvdGFibGVyYW5nZToyMWFiM2VjNGVjODk0ZWY5OTBiODc0YTgzMmVlODA3Yl8wLTEtMS0xLTE0ODM5NA_623d3b95-f98f-4b1c-8eee-76ecaa76b6f6">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6ODEzMzdiOTA4ZTVkNDUyNWE0NzE3MjcyYzIzZmZlYTkvdGFibGVyYW5nZTo4MTMzN2I5MDhlNWQ0NTI1YTQ3MTcyNzJjMjNmZmVhOV8xLTAtMS0xLTE0ODM5NA_53d81008-3090-4101-b620-3a03d6ee3516">Common Stock, Par Value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6ODEzMzdiOTA4ZTVkNDUyNWE0NzE3MjcyYzIzZmZlYTkvdGFibGVyYW5nZTo4MTMzN2I5MDhlNWQ0NTI1YTQ3MTcyNzJjMjNmZmVhOV8xLTItMS0xLTE0ODM5NA_8388de94-b990-4078-b4a9-3bea1e1e921b">NVAX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6ODEzMzdiOTA4ZTVkNDUyNWE0NzE3MjcyYzIzZmZlYTkvdGFibGVyYW5nZTo4MTMzN2I5MDhlNWQ0NTI1YTQ3MTcyNzJjMjNmZmVhOV8xLTQtMS0xLTE0ODM5NA_1ac6a8ab-414d-4be9-bace-6f9badedb7f5">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509"
      id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8xNDAz_980acec5-ebf2-4c80-9355-944d6097041b">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M#RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q
M_G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"
MIQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04    " !@/ZE6EXJ[',
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( & _J59"@>G#100  'H0   8
M          " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " !@/ZE6GZ ;\+$"  #B#   #0              @ &(#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( & _J5:7BKL<P    !,"   +
M  "  60/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( & _J589117U-P$  "<"
M   /              "  4T0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" !@/ZE6)!Z;HJT   #X 0  &@              @ &Q$0  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !@/ZE699!YDAD!  #/ P
M$P              @ &6$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
.."0 ) #X"  #@$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nvax-20230509.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="nvax-20230509.htm">nvax-20230509.htm</File>
    <File>a1q23earningspressrelease_.htm</File>
    <File>cicpressrelease_final.htm</File>
    <File>nvax-20230509.xsd</File>
    <File>nvax-20230509_lab.xml</File>
    <File>nvax-20230509_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nvax-20230509.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "nvax-20230509.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nvax-20230509_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nvax-20230509_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nvax-20230509.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "nvax",
   "nsuri": "http://www.novavax.com/20230509",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20230509.htm",
      "contextRef": "i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.novavax.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvax-20230509.htm",
      "contextRef": "i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001000694-23-000039-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001000694-23-000039-xbrl.zip
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MHN%QN53Z^T'^.AX,X-*>'T7^Z+A4++7&$5S1][T(5A+ D]6OZ@4SKXG$MZC
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ME%]D:L>FRP6$.-*.3%8Q\S!'X) XJHI3G!PI;S::Z#8.(#MU+_)Y.>#P^Y+
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M/[:\^ZCG.Q/X9QB-W/?_#U!+ P04    " !@/ZE6O2:+H=L2  "D5   &0
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M^$*8*"KRG'VI&.[]0)P:*YR63D5 AF]1Y\FNY@APG$EF*(^ ^<1RD\:8S-J
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MU".2X-\=XK^#_N[7)_C\SMR-9?_O4MK8V5S:V/9_OY/_DNB#_P)02P,$%
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M&J>QMVGVH$/IX*_FYU.[SX946._Z-CHE9:G[12=K,['")'S+BU9\&O3>[[%
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M,7HI4!><H KU)W06[QW<]MWF,LC"#]/ZO<_R+?I9T190 U28["&*6OKDJ6X
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MDY;KPMN(KPT?YJ?C,+J-6$*CV7.]?'1+%JP.K-"9P3_]9.A_^']02P,$%
M  @ 8#^I5F0;T.QM @  > <  !$   !N=F%X+3(P,C,P-3 Y+GAS9,U56V^;
M,!1^SZ_P>)ZY)6D!-:FT5I4F91=UK=JWR<$'8A5L9ILD_?>S'5!*VJR+M(?Q
M@CGG^\[]F(O+;5VA-4C%!)]YD1]Z"'@N*./ES+N_N\&)=SD?C2X^8/SXZ7:!
MKD7>UL UNI) -%"T87J%'BBH)U1(4:,'(9_8FF \=Z0KT3Q+5JXTBL-X?*B5
M&85X2B<AX'%""9Z0-,%)>'Z.T^F41.'D/(XC^K',IDD4YE&<XF@Y2?!D'">8
MD"G!$:63@IP!"<^H,[I5F<I74!-D$N,JVZJ9M]*ZR8)@L]GXF[$O9!G$81@%
MCU\6/QS4Z[ 5XT\#]'8IJQX_#JQZ213T<+XFVP&<BS4Q,C\7=6"S#:=AZB&B
MM63+5L.-D/4U%*2M],QK^:^65*Q@0$W%*[ U'0!>J#61)>BOI ;5D!S>]SD?
M(60KP>I&2(WXF\RN%%&:IL'6YN:A7>46(B?:C</14C@\MD<<Q7@<^5M%O>"O
MW X-,:XTX3F<XMM\X9[W+V+8]_6T&'K>Z3$X8PIROQ3K@ *SG8O?=J^.P>T!
MV\/0)^%<:,>WDD[6-(P78B<P(AMXUD=_"T6_*J_F_XT1<:^,R%R*ZIUY"AHI
M&I":@7JY.\[ 2D(Q\^P&X7YJ?U9DZ9M(>L@K!\,66'5@*% M]IGT7/W<&*XR
M#:A@5YO_.?%&PJF)&XHR-X9K](GY6_Z=T2-&9]Z5,'?_=U*:^*S\_O;ST=O%
M^=WC>Z.]60H%X\P-7NB>".']WP(CQT26>A$<$@Y,M0KH-SYWY\-$.W('^0,Q
M)U7>5J?S]F$=I77"OI#=H@7#3=M]O]A&)]BM^'ST&U!+ P04    " !@/ZE6
M43\94T<*   870  %0   &YV87@M,C R,S U,#E?;&%B+GAM;-5<76_;.A)]
M[Z_@>E]V@;(F)>J#19N+;FZ[*#:W+9H4O=C%PJ!(*A%J2X&L-,F_7U*V$RNF
M;)&*5>U+XMBCX9ECGN%H*.;-;W>+.?@IRV56Y&\G^!6: )GS0F3YY=O)MXL/
M,)[\=O+BQ9N_0/CG/[Z>@=\+?K.0>05.2\DJ*<!M5EV![T(N?X"T+!;@>U'^
MR'XR"$_JBTZ+Z_LRN[RJ@(<\_^FGY6LAO4 0)*$?"P8)HS&,411!&@0,(Q)Y
M'A8O+U\',48<>Q3BA,20^%X,&0L8Q$*0E(62H5#43N=9_N.U_I&PI00JN'Q9
M__EV<E55UZ^GT]O;VU=W23E_59274P\A?[JQGJS-[W;L;_W:&E-*I_6G#Z;+
MS&2HW.+IGW^<G?,KN6 PRY<5R[D>8)F]7M9OGA6<537G!W&!5@O]%]R80?T6
MQ![T\:N[I9B<O !@14=9S.57F0+]^]O7CZU#TJFVF.;R4G^S7V29%>*\8F5U
MQA(Y5^AK;]7]M7P[66:+Z[G<O'=5RM3L=EZ6#:\:)=4H<:A1_K5ML&D/^,^$
MM]K%^@S@ZG _/1?&?9Q^>C:X%RH_R.,#WAJF-^35A'J?BZ'F[L-0O:$?'_%S
M38NB8O,!IL7C,%N0Y_J-,_5J/8QVM">9UN.L4_<65'E7R5S(5;9LN :9>#M1
MKV9"9K/W>955]Z=JW2O9_*.ZX.Y?\GY&PBB,?+4H!5'"U=H5$,@\BM4:)245
MD6 $A;/J85+/9 Z_G6_&KP<Y,,+$(K:J1:.E7!8W)7]<W19STY*E5BN]OL73
MG"WD\IJM+U P=2&P0GZR @G6*$$-$RB<;Z:/(;D0.3\^/?.1,5/P!I:Y+@>*
M\FGT!3\<_:.^E@IX'?I2\E>7Q<^INE91X'GZ!=0O:EFU>YSN?'GOR@U.5O(#
M/*\MIKQ0M<YU!1N4Z]JP8T!5T?%[7U&GAIV HA2R5/6K(03#_+M@=Q^%\IFE
MV:H*^W2S2&0YBV44IX13F/B"0!((JNI0'\$4$X_Z:8($L11TRT@C%;9""YIP
MP0JOK<#;".XJ]&>@;1C!VS/F(/P#;/1( &V>!TX$!P+<30B'+G!-#.^$4)-D
MN?ZEJ@N)9Y' .$Q9"@,6!Y"@6,#$(PG$G&-&14@PBNV2@F&4D2:$-<27FQ=
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M1#S# T=[CR>ZE^[!^*.]_P)02P$"% ,4    " !@/ZE639=2%; C  #;( $
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I87@M,C R,S U,#E?<')E+GAM;%!+!08     !@ & )<!  ":9P     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
